fda bpc-157 compounding restrictions Is Legal in 2026? Status Explained BREAKING: The FDA just reversed

FDA concluded there is insufficient clinical safety information to characterize its human safety profile, and found no studies administering it to humans by the proposed routes

These effects, when present, are typically manageable and resolve with continued use or dose adjustment

Safety advice Not for use during pregnancy or breastfeeding unless specifically advised by a clinician

1 Press release, July 3, 2026, ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI 2 Press Release, July 5, 2023, ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing 3 Press Release, July 25, 2025, ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone Lispro (THDB0206 injection) in people with T2D 4 Press Release, October 15, 2025, ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone Lispro (THDB0206 injection) in people with T1D 5 GMP = Good Manufacturing Practices 6 P ress Release, November 12, 2025, ADOCIA Announces Filing of Patent for New Long-Acting Peptides Platform in Diabetes and Obesity - AdoXLong - and Provides an Update on its BioChaperone Platform Adocia Olivier Soula CEO [email protected] +33 (0)4 72 610 610 www.adocia.com Maarc Adocia Press & Investor Relations Bruno Arabian Yasmine Duval Thomas Rolnik [email protected] + 33 (0)6 87 88 47 26 View source version on businesswire.com: The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties

| 2024 Edition Researchers looking to delve into the benefits of TB-500 will find multiple vendors offering this peptide for sale online